In a bid to acquire the minority stake in the Mumbai-based firm for a cash consideration of Rs 10.5 crore, Goldencross Pharma, a wholly-owned subsidiary of Cipla, has signed an agreement.

Drug major CiplaNSE 0.81 % recently revealed that it has inked a pact to acquire 11.71 per cent stake in Wellthy Therapeutics.

It was revealed that as part of the agreement, the partners plan to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.

Also read: Medlife to open 750 retail pharmacies across country

A multi-lingual clinically-validated digital disease management platform will be made available, as per the agreement,  to patients living with diabetes or cardiovascular diseases via doctors’ clinics or co-packaging on select Cipla brands.

The forum brings together behavioural science, real-world clinical evidence and artificial intelligence to provide real-time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

The transaction is expected to close before March 10.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!